VAERS reports by lot

Moderna COVID-19 lot 059M21A: VAERS reports

383 VAERS reports list lot 059M21A as a Moderna COVID-19 vaccine, received between 2022-03-10 and 2023-12-29. Data: VAERS public files through 31 December 2024 (site extract 2026-07-04).

Read this first. VAERS accepts reports from anyone, and a report does not establish that the vaccine caused the event. A lot's report count mostly reflects how many doses it contained, when it was used and who received it; no administered-dose counts are published for this lot, so counts are not rates and cannot rank lots against each other. Lot numbers in VAERS reports are typed by reporters and are sometimes wrong.
383
Reports
27%
Marked serious
8
With a death outcome
21
Months with reports

Symptom categories in these reports

A report can mention several categories, so the counts add up to more than the number of reports.

CategoryCount%
General / Systemic (non-local)34425%
Gastrointestinal19314%
Respiratory18413%
Neurological15511%
Cardiac / Cardiovascular15211%
Injection-site / Local reaction1078%
Musculoskeletal745%
Allergic / Anaphylactic584%
Dermatological (non-injection-site)514%
Thrombotic / Hematological302%
Psychiatric / Neuropsychiatric302%
Autoimmune / Immune-mediated81%
Reproductive / Menstrual30%

Where reports came from

U.S. state of the reporter, where given (top 12).

Michigan59
Massachusetts35
California22
Illinois15
New York15
Georgia13
Texas12
Virginia12
Indiana11
Florida11
Ohio11
Colorado9

Reports by month received

2022-031
2022-0570
2022-0680
2022-0776
2022-0819
2022-0920
2022-1020
2022-1120
2022-1218
2023-015
2023-0214
2023-0311
2023-048
2023-059
2023-064
2023-071
2023-081
2023-092
2023-101
2023-111
2023-122

Products recorded with this lot

Manufacturer and product as reported in VAERS. Reports listing the lot under more than one product are counted once.

Related

Source: VAERS public data (CDC/FDA), grouped by manufacturer and lot by the Open Source Medicine Foundation; extract 2026-07-04 16:35 UTC. Not medical advice. Report errors via contact.